Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Real-world evolution of first-line ALK-positive NSCLC management in Spain.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calvo Virginia, Zugazagoitia Jon, García Elisabet, Villa Gerardo, Montes Antonio José
Аннотация
OBJECTIVE: To describe real-world management of patients with ALK-positive advanced or metastatic NSCLC receiving first-line therapy in Spain, and to assess shifts in treatment patterns following the pricing and reimbursement of lorlatinib for first-line treatment in Spain.
METHODS: This retrospective, cross-sectional analysis used data from the IQVIA Oncology Dynamics™ database. Patients with ALK-positive advanced or metastatic NSCLC receiving first-line treatment in Spain were included in two cohorts: before (July 2021-June 2022) and after (July 2024-June 2025) lorlatinib introduction. Patient characteristics, molecular profiles, and treatment patterns were described using descriptive statistics.
RESULTS: A total of 342 patients were included. Patient characteristics were generally comparable across cohorts, although a higher disease burden and increased frequency of brain metastases were observed over time. A marked shift in treatment patterns was reported, with lorlatinib use increasing from 2 to 46% and becoming the most frequently prescribed first-line therapy in the later cohort, while alectinib use decreased from 85 to 41%. Among newly treated patients, lorlatinib accounted for 67% of prescriptions in the later cohort. Uptake of next-generation sequencing for molecular testing increased, and radiotherapy use declined over time.
CONCLUSIONS: The management of ALK-positive NSCLC in Spain has evolved following the pricing and reimbursement of lorlatinib for first-line treatment in Spain, with changes in treatment selection and molecular testing practices observed in routine clinical settings.
METHODS: This retrospective, cross-sectional analysis used data from the IQVIA Oncology Dynamics™ database. Patients with ALK-positive advanced or metastatic NSCLC receiving first-line treatment in Spain were included in two cohorts: before (July 2021-June 2022) and after (July 2024-June 2025) lorlatinib introduction. Patient characteristics, molecular profiles, and treatment patterns were described using descriptive statistics.
RESULTS: A total of 342 patients were included. Patient characteristics were generally comparable across cohorts, although a higher disease burden and increased frequency of brain metastases were observed over time. A marked shift in treatment patterns was reported, with lorlatinib use increasing from 2 to 46% and becoming the most frequently prescribed first-line therapy in the later cohort, while alectinib use decreased from 85 to 41%. Among newly treated patients, lorlatinib accounted for 67% of prescriptions in the later cohort. Uptake of next-generation sequencing for molecular testing increased, and radiotherapy use declined over time.
CONCLUSIONS: The management of ALK-positive NSCLC in Spain has evolved following the pricing and reimbursement of lorlatinib for first-line treatment in Spain, with changes in treatment selection and molecular testing practices observed in routine clinical settings.